CIPLA: News
Sensex, Nifty break gaining streak; HDFC Bank tanks nearly 5%
On July 5, benchmark indices Nifty and Sensex ended their two-day gaining streak, with the Sensex falling by 0.57% to 79,590 and the Nifty slipping by 0.44% to 24,194.
Sensex gains over 130 points, Nifty settles near 23,540 mark
On Monday, major indices of the stock market, Sensex and Nifty, ended on a high.
Sensex, Nifty close in red after touching record highs
On Monday, the stock market witnessed a slump after hitting record highs.
Sensex gains over 250 points, Nifty ends above 22,460 mark
On Friday, the benchmark Sensex and Nifty indices showed an upward trend.
Sensex gains 260 points, Nifty settles above 22,050 mark
On Friday, the benchmark Sensex and Nifty indices saw some gains after trading in the red for several sessions.
PLI schemes attract over Rs. 1L crore investments until December
Indian government data reveals that production-linked incentive (PLI) schemes across 14 sectors have attracted investments exceeding Rs. 1.06 lakh crore up to December 2023.
Cipla clocks 45% YoY profit growth in Q2 FY24
Cipla declared its Q2 FY24 financial results today, showcasing a net profit of Rs. 1,155.37 crore, a whopping 44.9% growth compared to Rs. 797.41 crore in Q2 FY23.
Torrent secures funding to buy 33% stake in Cipla
Torrent Pharmaceuticals Ltd. is reportedly eyeing a 33% stake in Mumbai-based drugmaker Cipla, having secured at least $5 billion in funding from a group of overseas banks.
Torrent Pharma seeks $1 billion loan for Cipla bid
India's Torrent Pharmaceutical is in preliminary discussions with Apollo Global Management to secure a loan of up to $1 billion, aiming to fund a planned bid for its larger rival, Cipla, according to Reuters.
Sensex gains nearly 420 points, Nifty settles above 18,700 mark
On Tuesday, the benchmark Sensex and Nifty indices saw gains. While the Sensex rose 0.66% to settle at 63,143.16 points, the Nifty jumped 0.61% to 18,716.15 points.
Sensex closes at 58,774 points, Nifty settles at 17,522
The stock market on Thursday ended on a sluggish note as the Sensex fell by 0.53% to settle at 58,774.72 points, while the Nifty declined by 0.47% to end at 17,522.45 points.
Cipla gets DCGI nod to import Moderna COVID-19 vaccine
The Drugs Controller General of India (DCGI) has reportedly allowed the pharmaceutical firm Cipla to import the COVID-19 vaccine developed by US-based biotechnology company Moderna Inc.
Roche's Antibody Cocktail launched in India, priced at Rs. 59,750/dose
Drug majors Roche India and Cipla on Monday announced the launch of Roche's Antibody Cocktail in India priced at Rs. 59,750 per dose for treatment of mild to moderate COVID-19 in patients who are at high risk.
Coronavirus: Zydus Cadila launches cheapest version of Remdesivir in India
In a major development, Zydus Cadila has launched the cheapest generic version of Remdesivir, the antiviral drug being used to treat COVID-19, in India.
Coronavirus: 5 states to receive first batch of Hetero's COVIFOR
Five states across India will be the first to receive Hetero Healthcare's COVID-19 drug, COVIFOR, the first generic brand of the experimental drug remdesivir.
These drugs are in use for COVID-19 treatment in India
India has opened up, but the pandemic is not slowing down.
India's five most influential and successful women in finance
The world of finance used to be seen as an industry only for men for the longest time. However, that has changed in the last few years.
Cipla's new strawberry-flavored medicine can save kids from AIDS
In a bid to save thousands of children from HIV AIDS, Indian pharmaceutical company Cipla has introduced a revolutionary new drug called Quadrimune.
India's five most influential and successful women in finance
The world of finance used to be seen as an industry only for men for the longest time. However, that has changed in the last few years.
Cipla boss calls Subhanu Saxena quits; cites family reasons
Cipla chief executive Subhanu Saxena confirmed that he would no longer be serving as the head of the company.